Posts

OPKO Health Receives U.S. FDA Approval for the 4Kscore® Test

MIAMI, Dec. 08, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that the U.S. Food and Drug Administration (FDA) has approved OPKO’s 4Kscore Test. This test is approved for use in men age 45 and older who have…

BioReference Laboratories Acquires U.S. Ariosa Centralized Laboratory Prenatal Testing Business

ELMWOOD PARK, N.J., August 16, 2021 – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced the acquisition of the U.S. Ariosa centralized laboratory prenatal testing business from Roche. Ariosa's…

Keeping Cancer Screening at the Forefront

To undergo cancer screening is a choice that we make- similar to diet, lifestyle, and other habits that can influence our overall health and well-being. However, the onset of the COVID-19 pandemic has resulted in disruptions to many aspects…

Acting FAST to Save from Strokes

Did you know – Stroke kills twice as many women as breast cancer does, making stroke the third leading cause of death for women., according to the CDC.* May is American Stroke Awareness Month, a time to time to learn about the signs of stroke,…

Cervical Cancer Awareness Month

January is Cervical Cancer Awareness Month and a reminder that the most important thing you can do to prevent cervical cancer is to start screening at the age of 21.  The American Cancer Society estimated that about 13,800 new cases of invasive…

OPKO Health’s BioReference Laboratories Launches Best-in-Class Next-Generation Sequencing (NGS) Assay

,
ELMWOOD PARK, N.J., September 2, 2020 — BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), along with its specialty oncology division, GenPath, today announced the launch of OnkoSight AdvancedTM, a next-generation sequencing…